Suchergebnisse
Suchergebnisse:
Paul Carbone um 1934. Paul Carbone (* 15. Februar 1894 in Propriano, Korsika; † 16. Dezember 1943 nahe Chalon-sur-Saône, Frankreich) war ein Krimineller im Marseiller Halbwelt -Milieu. In den 1920er Jahren entwickelte er sich zum mächtigsten Mafia -Boss Marseilles, und in den 1930er Jahren bis zu seinem gewaltsamen Tod 1943 war ...
Paul Bonnaventure Carbone (1 February 1894 – 16 December 1943) was a Corsican criminal involved in the Marseille underworld from the 1920s until his death in 1943. He was known as the Emperor of Marseille.
Paul Carbone is a private equity investor and co-founder of Pritzker Private Capital (PPC), a family-owned and operated investment firm. He has over 30 years of experience in M&A, investment banking, and private equity, and serves on several boards and advisory roles.
Paul Carbone is a co-founder and vice chairman of Pritzker Private Capital, a family-owned investment firm. He has a Harvard Business School degree and serves on several boards and committees, including the University of Chicago and the Art Institute of Chicago.
- 500+
- Pritzker Private Capital
- 3.4K
- Chicago, Illinois, United States
Paul Carbone war ein Krimineller im Marseiller Halbwelt-Milieu. In den 1920er Jahren entwickelte er sich zum mächtigsten Mafia-Boss Marseilles, und in den 1930er Jahren bis zu seinem gewaltsamen Tod 1943 war er dort gemeinsam mit seinem Partner François Spirito eine der zentralen Figuren. Der Film Borsalino mit Alain Delon als Roch Siffredi ...
In Memoriam. Paul Carbone: 1931-2002. A gentle giant has left the stage of oncology. Paul Carbone passed away unexpectedly at the age of 70, leaving the whole field stunned and saddened. I first met Paul Carbone in 1963 at the Medicine Branch of the National Cancer Institute (NCI) during a very heady time in the history of oncology.
1. Apr. 2002 · A gentle giant has left the stage of oncology. Paul Carbone passed away unexpectedly at the age of 70, leaving the whole field stunned and saddened. I first met Paul Carbone in 1963 at the Medicine Branch of the National Cancer Institute (NCI) during a very heady time in the history of oncology.
